English (UK)
中文版Jupiter Orphan Therapeutics Inc. (JOT) 
Christer Rosen
Chairman & CEO
Kymeris Therapeutics Inc. 
Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.
* We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.
* We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.
------------------------------------------------------------------
The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents. It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.
The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications, enhanced effect and much safer profile. In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).
The platform has shown the following characteristics:
1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally.
2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.
3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled. Any agents outside of the TME were naturally cleared in under 10 days.
Richard McCrae
President & CEOmaintect GmbH 
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.
Prof. Dr. Dr. Franz Grus
CEO
MSL Pharma 
As an early-stage company, in order to reduce overhead costs, we effectively act as the project manager – we plan the assays and subcontract the early development stages to university labs, and the later stages to CROs that specialize in the different fields. The Company monitors the results, determines next steps and fundraises for the next phases of development. We believe that working with leading experts at CROs is critical for success.
The Company has licenses for platform technologies which are progressing to several different projects; as such it is planning to out-license at various stages of development.
Synthesis of cyclic peptides which are peptidomimetics
MSL Pharma has the capability to identify “active regions” of proteins and peptides, to isolate them and to turn them into cyclic peptides which are selective for the desired receptors and stable, thereby preventing off-target activation and adverse effects (see Asset, Table 1).
Drug delivery systems for peptides and other molecules
MSL Pharma has two technologies for drug delivery (see Mode of Delivery, Table 1) that achieve unprecedented bioavailability:
1. Lipophilic prodrug charge masking (LPCM) technology for the oral delivery of peptides. This technology makes a chemical modification in a peptide to be converted to oral delivery, to produce a prodrug of this peptide. This causes it to be absorbed through the intestinal cell and once the prodrug enters the blood stream, it converts back to the original peptide. Typically, the Pgp Efflux system limits the prodrug absorption; we have overcome this with an approved self-assembling PNL (pro-nano liposphere) encapsulation system, itself a self-nanoemulsifying drug delivery system (SNEDDS), which increases prodrug solubility and inhibits the Pgp Efflux system.
2. A novel nanoparticle formulation called AmyloLipid Nanovesicles which is constructed of natural materials and therefore safe ,biodegradable and has an advantage for the delivery of peptides. This technology is used also for the delivery of other molecules, can be used for nose-to-brain, sublingual, transdermal and probably also oral delivery, and can be applied to our assets (Table 1) or existing assets (Table 2).
A novel smart multi-armed linker for targeted drug delivery
Our linker can be used for peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs) and nanoparticle-drug conjugates (NDCs). Our linker releases the payload (chemotherapeutic drug or fluorescent) only in the tumor cells and can bind up to three payloads (see Table 3). We have demonstrated that using two or three different drug payloads kills the tumor cells more potently and with less drug resistance developing.
Discovery of novel peptides for peptide-drug conjugates
We have technologies to synthesize novel peptides which will bind to receptors overexpressed in certain tumors so that we will be able to use them for synthesizing peptide-drug conjugates (PDCs) to diagnose and treat different tumors. We already have at our disposal peptides that bind to the five different somatostatin receptors (overexpressed in pancreatic, gallbladder, breast, ovary, prostate, melanoma, lymphoma, glioblastoma, colon and non-small-cell lung tumors) and to certain integrin receptors (overexpressed in tumors such as breast, glioblastoma, leukemic cells).
Dr Yarom Cohen
CEO
Nodes Advisors AG 
We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.
Eliott Harfouche
Partner
Ping Rawson
Dyadic International, Inc. is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, based on a patented and proprietary genetically modified strain of the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), to address opportunities in the human and animal health markets. C1 is a potentially game-changing biopharmaceutical gene expression platform that may help bring biologic vaccines, drugs and other biologic products to market faster and more efficiently than existing expression platforms, such as Chinese hamster ovary (CHO) cells, E. coli, yeast and baculovirus in greater volumes, at lower cost and with new properties that can improve access and cost to patients and the healthcare system.
CFO
REM Analytics SA
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.
Paulo Refinetti
Dr.
Rius Medical UG (Haftungsbeschränkt)
Mr Denis Demarais
Founder and CEO
Simcere Pharmaceutical Group 
We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”
Responsive Web Design powered by 